U.S. Stock Market Movement | Weight-loss concept stocks rise, Eli Lilly up more than 6.8%

On Friday, US stocks related to the weight loss concept rose. As of the time of publication, Eli Lilly rose by over 6.8% to $903, while Novo Nordisk rose by nearly 4.6% to $134.04. In the second quarter, Eli Lilly's net profit was $2.97 billion, a year-on-year increase of 68%; revenue was $11.3 billion, a year-on-year growth of 36%, exceeding market expectations of $9.92 billion; adjusted earnings per share were $3.92, surpassing the expected $2.60. The weight loss drug Zepbound, which received FDA approval for listing in November last year, contributed revenue of $1.24 billion in the second full quarter, exceeding market expectations of $920 million. Due to the strong performance of the weight loss drug, the company has raised its fiscal year revenue guidance for the second time this year: both ends of the revenue guidance have increased by $3 billion to $45.4 to $46.6 billion; full-year adjusted earnings per share are $16.10-16.60, up from the previous guidance of $13.50 to $14